Renal denervation's a huge opportunity for Medtronic, St. Jude Medical, and other leading device companies, but recent setbacks have investors wondering how long it will be before potential translates into results
Johnson & Johnson rarely gets much attention for its efforts in diabetes treatments. Let’s take a look at three of the company’s interesting new efforts to treat diabetes, and how they could affect companies like AstraZeneca, Bristol-Myers Squibb, Medtronic, DexCom, and Sanofi.
Boston Scientific, St. Jude Medical, and Medtronic put on a show for investors in 2013, but can they keep up their momentum in the new year?
Abbott Labs hasn't slowed down in its post-pharmaceutical life, but 2014 brings reasons for investors to believe in this sturdy stock.
A potential $3 billion/year therapy may not work nearly as well as hoped.
New technology that tracks blood sugar is driving sales and share higher at Dexcom.
Humanoid first-responders are coming, and for Lockheed, that could spell profits.
Covidien's purchase of Given Imaging is a little pricey, but could unlock powerful marketing leverage down the road.
Volcano, Intuitive Surgical, and Edwards Lifesciences have taken a hit this year. Should you trust that a turnaround is on the way?
Stocks wobble despite strong economic data as the Dow Jones sheds earlier gains